WHO launches online data collection for leprosy
WHO has launched an online data collection tool for leprosy which now facilitates the collection of epidemiological and programmatic indicators from Member countries.
The tool, modelled on the DHIS-2 platform, merges for the first time, epidemiological data and information on stock levels of multi-drug therapy*], MDT.
This simplifies reporting requirements by endemic countries and allows WHO to monitor progress for the control of leprosy at global level.
The old practice of dual data collection (within a few months from each other) is now discontinued.
* The combination used in MDT depends on the classification of leprosy. Rifampicin, the most important antileprosy medicine, is included in the treatment of both types of leprosy. For the treatment of patients with multibacillary leprosy, WHO recommends a combination of rifampicin, clofazimine and dapsone; for patients with paucibacillary leprosy, MDT uses a combination of rifampicin and dapsone.